Inflammation in Metabolic Cardiomyopathy

Area of Science:

• Cardiovascular Medicine
• Metabolic Disorders
• Immunology

Background:

• Lifestyle-related diseases, including obesity, insulin resistance, and diabetes, significantly threaten cardiovascular health.
• Metabolic disturbances drive systemic inflammation, which exacerbates cardiovascular disease by affecting myocardial structure and function.
• Inflammatory signals are central to the mechanisms linking metabolic dysregulation to cardiac damage.

Purpose of the Study:

• To review the current evidence on inflammatory processes in the development of metabolic cardiomyopathy (MC).
• To provide an overview of nutrient and cytokine-driven pro-inflammatory effects on cardiac cells.
• To highlight potential therapeutic targets for MC by examining the interplay between inflammation and cardiac metabolism.

Main Methods:

• Literature review of preclinical and observational studies.
• Analysis of cellular and molecular mechanisms linking inflammation to cardiac dysfunction.
• Stratification of pro-inflammatory effects by cell type and specific pathways.

Main Results:

• Metabolic dysregulation induces systemic inflammation, leading to cardiac cell alterations, oxidative stress, mitochondrial dysfunction, and lipotoxicity.
• Myocardial inflammation, driven by innate immune cell activation (e.g., TLR4, NLRP3 inflammasome, NF-κB), promotes maladaptive remodeling.
• Chronic inflammation progresses to a metabolic cardiomyopathy phenotype, often associated with heart failure with preserved ejection fraction (HFpEF).

Conclusions:

• Inflammation is a key driver of metabolic cardiomyopathy, linking metabolic disturbances to heart failure.
• Targeting inflammatory mediators, closely linked to cardiac nutrient metabolism, represents a potential therapeutic avenue for MC.
• Understanding cell-specific inflammatory responses is crucial for developing effective treatments for cardiometabolic diseases.